However, a recent meta-analysis of four phase II-III trials testing lapatinib in combination with neoadjuvant trastuzumab plus chemotherapy for HER2+ early BC has provided robust evidence that this dual HER2 blockade prolongs overall survival (HR 0.65, 95% CI 0.43–0.98). This evidence concerns the gene ERBB2 and breast cancer.